RNLXY · Renalytix plc
$4.15
-0.34 (-7.47%)
At close · Sep 4
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$2.20M
Shares
529,930
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$2.29M
-32.7%
FY2024
Net Income
-$33.46M
+26.6%
FY2024
Gross Margin
6.82%
-14.3pp
FY2024
Operating Margin
-1293.49%
-52.8pp
FY2024
Diluted EPS
-$193.75
+43.6%
FY2024
Operating Cash Flow
-$30.11M
+11.7%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $2.35M | $2.29M | $3.4M | $2.97M | $1.49M | $0 | — | |
| $2.05M | $2.13M | $2.68M | $2.1M | $858K | $0 | — | |
| $299K | $156K | $720K | $874K | $633K | $0 | — | |
| — | 6.82% | 21.16% | 29.43% | 42.45% | — | — | |
| $7.42M | $9.29M | $14.3M | $14.65M | $10.04M | $4.57M | $4.32M | |
| $16.96M | $19.75M | $28.66M | $39.52M | $23.48M | $5.75M | $2.74M | |
| $297K | $364K | $508K | $489K | $282K | $70K | $31K | |
| $25.11M | $29.76M | $42.94M | $54.06M | $32.55M | $10.32M | $42.34M | |
| -$24.81M | -$29.61M | -$42.22M | -$53.18M | -$31.92M | -$10.32M | -$42.34M | |
| — | -1293.49% | -1240.7% | -1790.67% | -2140.58% | — | — | |
| -$24.52M | -$29.24M | -$41.71M | -$52.69M | -$31.63M | -$10.25M | -$42.31M | |
| $144K | $249K | $656K | — | $726K | $289K | $18K | |
| — | $0 | -$9000 | $9000 | -$2.11M | -$63K | — | |
| -$28.02M | -$33.45M | -$45.61M | -$45.25M | -$35.34M | -$9.84M | -$42.3M | |
| $6000 | $4000 | $2000 | $25K | $0 | $0 | — | |
| -$28.03M | -$33.46M | -$45.61M | -$45.28M | -$35.34M | -$9.84M | -$42.3M | |
| — | -1461.6% | -1340.2% | -1524.44% | -2369.95% | — | — | |
| — | — | — | $0 | $611K | $0 | — | |
| — | — | — | -$45.28M | -$34.73M | -$9.84M | -$42.3M | |
| — | — | — | -$54.47M | -$25.76M | -$10.22M | -$43.13M | |
| USD/shares | -$150.00 | -$193.75 | -$343.75 | -$387.50 | -$306.25 | -$106.25 | — |
| USD/shares | -$150.00 | -$193.75 | -$343.75 | -$418.75 | -$306.25 | -$106.25 | — |
| shares | — | 173.09K | 131.54K | 116.58K | 114.38K | 94.53K | 68.1K |
| shares | — | 173.09K | 131.54K | 118.14K | 114.38K | 94.53K | 68.1K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.